226 related articles for article (PubMed ID: 38562891)
1. Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite.
McMorrow HE; Lorch CM; Hayes NW; Fleps SW; Frydman JA; Xia JL; Samms RJ; Beutler LR
bioRxiv; 2024 Mar; ():. PubMed ID: 38562891
[TBL] [Abstract][Full Text] [Related]
2. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
3. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
4. AgRP Neurons Can Increase Food Intake during Conditions of Appetite Suppression and Inhibit Anorexigenic Parabrachial Neurons.
Essner RA; Smith AG; Jamnik AA; Ryba AR; Trutner ZD; Carter ME
J Neurosci; 2017 Sep; 37(36):8678-8687. PubMed ID: 28821663
[TBL] [Abstract][Full Text] [Related]
5. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
[TBL] [Abstract][Full Text] [Related]
6. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
7. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological antagonism of the incretin system protects against diet-induced obesity.
Svendsen B; Capozzi ME; Nui J; Hannou SA; Finan B; Naylor J; Ravn P; D'Alessio DA; Campbell JE
Mol Metab; 2020 Feb; 32():44-55. PubMed ID: 32029229
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
[TBL] [Abstract][Full Text] [Related]
10. Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control.
Craig SL; Gault VA; Shiels CE; Hamscher G; Irwin N
Biochim Biophys Acta Gen Subj; 2021 Aug; 1865(8):129917. PubMed ID: 33964357
[TBL] [Abstract][Full Text] [Related]
11. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
Spielman LJ; Gibson DL; Klegeris A
Eur J Cell Biol; 2017 May; 96(3):240-253. PubMed ID: 28336086
[TBL] [Abstract][Full Text] [Related]
12. Obesity pharmacotherapy: incretin action in the central nervous system.
Boer GA; Hay DL; Tups A
Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
[TBL] [Abstract][Full Text] [Related]
13. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
14. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
15. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
16. New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar M
Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
[TBL] [Abstract][Full Text] [Related]
17. Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches.
Boer GA; Holst JJ
Biology (Basel); 2020 Dec; 9(12):. PubMed ID: 33339298
[TBL] [Abstract][Full Text] [Related]
18. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
19. GIP and GLP-1, the two incretin hormones: Similarities and differences.
Seino Y; Fukushima M; Yabe D
J Diabetes Investig; 2010 Apr; 1(1-2):8-23. PubMed ID: 24843404
[TBL] [Abstract][Full Text] [Related]
20. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
